Overview

A Study to Investigate Pharmacokinetics (PK) and Safety of a Single Dose of Mavorixafor in Participants With Hepatic Impairment (HI) Compared to Matched Healthy Volunteers With Normal Hepatic Function

Status:
RECRUITING

Trial end date:
2026-04-01

Target enrollment:

Participant gender:

Summary

The purpose of this study is to measure the effect of HI on the PK, safety, and tolerability of a single dose of mavorixafor compared to matched healthy volunteers (HVs) with normal hepatic function.

Phase:

PHASE1

Details

Lead Sponsor:

X4 Pharmaceuticals

Treatments:

mavorixafor